Condition

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (4)

Multifocal Motor Neuropathy (MMN) (1)

Overall Status

Completed (2)

Active, not recruiting (1)

Recruiting (1)

Sign in for free

Phase

phase 2 (2)

phase 3 (1)

Sponsor

Takeda (2)

Nagoya University (1)

UCB Biopharma SRL (1)

Collaborator

Baxalta Innovations GmbH, now part of Shire (1)

Japan Agency for Medical Research and Development (1)

RTI Health Solutions (1)

Zenyaku Kogyo Co., Ltd. (1)

Intervention

placebo (1)

rituximab (genetical recombination) (1)

rozanolixizumab (1)

tak-771 (1)

Study Documents

Intervention Type

drug (2)

biological (1)

other (1)

Funder Type

Industry (3)

Other (1)

Study Type

Interventional (3)

Observational (1)

chronic inflammatory demyelinating polyradiculoneuropathy (cidp)

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Multifocal Motor Neuropathy (MMN) Trial in Japan (TAK-771)

Recruiting

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Multifocal Motor Neuropathy (MMN)

TAK-771

Nagoya, Aichi, Japan
+16 more

Feb 2, 2023

GAMMAGARD LIQUID in Chronic Inflammatory Demyelinating

Active, not recruiting

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Durham, North Carolina

RTI Health Solutions

Jun 14, 2022

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Trial in Worldwide (Rozanolixizumab)

Completed

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Rozanolixizumab

Scottsdale, Arizona
+13 more

Mar 31, 2022

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Trial in Japan (Rituximab (genetical recombination), Placebo)

Completed

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Rituximab (genetical recombination)
Placebo

Nagoya, Aich, Japan
+3 more

Aug 19, 2021